MétaCan
Menu
Back to cohort
Record W4416564553 · doi:10.1136/bmjgh-2025-018960

The association between drug shortages and prices across 74 countries: uncovering global access inequities

2025· article· en· W4416564553 on OpenAlexaff
Shuchen Hu, Araniy Santhireswaran, Cherry Chu, Shanzeh Chaudhry, Caijun Yang, Yu Fang, Katie J. Suda, Étienne Gaudette, Quinn Grundy, Mina Tadrous

Bibliographic record

VenueBMJ Global Health · 2025
Typearticle
Languageen
FieldEconomics, Econometrics and Finance
TopicPharmaceutical Economics and Policy
Canadian institutionsWomen's College HospitalUniversity of Toronto
Fundersnot available
KeywordsEconomic shortagePer capitaGlobal healthAssociation (psychology)Health policyInequalityGlobal South

Abstract

fetched live from OpenAlex

BACKGROUND: Drug shortages are a global concern that poses risks to clinical care and health systems. Lower prices and market pressures are often cited as drivers of drug shortages; thus, a commonly proposed policy lever is to increase drug prices. However, global evidence to evaluate the association between shortages and prices is lacking. This research aims to fill the gap by examining the global markets of drug shortages. METHOD: We included 25 global shortage markets by reviewing publications on drug shortages from 2013 to 2023. We used quarterly pharmaceutical sales data across 74 countries/regions from the IQVIA MIDAS quarterly sales volume data database from Q3 2011 to Q3 2022. Our outcome of interest was shortage intensity, defined as the drug shortage duration between its onset and the end of meaningful shortages. To assess the impact of price on the occurrence and intensity of shortages, we used zero-inflated negative binomial regression, with price as the independent factor and included gross domestic product (GDP) per capita and the number of manufacturers as covariates. P values less than a Bonferroni-corrected significance level (0.00625) were considered statistically significant. RESULTS: Out of 1096 subjects (each representing a drug market in a specific country), 65% (712 subjects) experienced meaningful shortages with a median shortage intensity of 10 quarters. We found price was not a significant predictor of either shortage odds (p=0.044) or intensity (p=0.066). Factors significantly associated with increased odds of a non-shortage occurrence included a unit increase in GDP per capita (adjusted OR (aOR): 1.707, 95% CI 1.428 to 2.040) and in the number of manufacturers (aOR: 4.038, 95% CI 3.045 to 5.354), corresponding to 70.7% and 303.8% higher odds, respectively. A unit increase in GDP per capita was significantly associated with a 10.4% decrease (adjusted rate ratios: 0.896, 95% CI 0.834 to 0.962) in the duration of shortage intensity. CONCLUSION: Our study reveals global inequities in the impact of drug shortages, with countries with lower GDP per capita disproportionately affected. Persistent shortages of essential medications have been observed worldwide over the past decade, but are not evenly distributed across countries. Collectively, our findings suggest the need to consider creative and alternative policy strategies beyond pricing to address both critical drug shortages and global inequities in shortage experiences.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.009
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.014

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.009
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0040.007
Science and technology studies0.0000.001
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.051
GPT teacher head0.427
Teacher spread0.376 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueBMJ Global HealthSame topicPharmaceutical Economics and PolicyFrench-language works237,207